Apricus Biosciences (APRI) Receives FDA Clearance for Second NexACT OTC Anti-Itch Drug
Tweet Send to a Friend
Apricus Biosciences, Inc. (Nasdaq: APRI), reports its wholly owned subsidiary, NexMed USA, has received clearance from the U.S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
